Why Topiramate Matters
Topiramate is an anticonvulsant approved for epilepsy and migraine prevention, and psychiatrists mostly prescribe it for things on neither list: heavy drinking, antipsychotic weight gain and binge eating. It is one of the few psychotropics that takes weight off. Of its four labeled actions, carbonic anhydrase inhibition accounts for two distinctive harms, metabolic acidosis and kidney stones.
The psychiatric evidence is uneven. In alcohol use disorder most placebo-controlled trials were positive, the 2018 APA guideline suggests it (2C) after or instead of naltrexone and acamprosate, and in a 2024 head-to-head trial the authors judged it at least as effective as naltrexone. For antipsychotic weight gain, meta-analyses in schizophrenia put it roughly 3 to 4 kg below placebo, close to metformin in an indirect comparison. Two placebo-controlled trials support it in binge-eating disorder. It failed in acute mania (four monotherapy trials, one add-on trial), and the PTSD and stimulant data are small and mixed.
What patients pay is mostly cognitive: slowed thinking, trouble finding words, poor concentration, along with tingling and a change in how food and drinks taste. The label ties cognitive effects to fast titration and higher doses, which is the main reason to go slowly. It is also a teratogen (oral clefts, small-for-gestational-age babies), and Nordic registry analyses linked it to autism, intellectual disability and ADHD, while a large US analysis found the autism association largely disappeared after adjustment.
Use topiramate as a second-line option: for heavy drinking after naltrexone or acamprosate (or first when opioids rule naltrexone out), for antipsychotic weight gain after metformin or a GLP-1 agonist, and for binge eating when a stimulant is a poor fit. Move it up the list when two of those problems, or migraine, occur together. Raise it 25 mg a week, check bicarbonate, warn about word-finding, eye pain and kidney stones, settle contraception before the first dose, and never use it as a mood stabilizer.
Part 1: Indications
FDA-Approved Uses
- Epilepsy, initial monotherapy for partial-onset or primary generalized tonic-clonic seizures, age 2 and older (Topamax, Qudexy XR, Eprontia; Trokendi XR from age 6)
- Epilepsy, adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic seizures and seizures of Lennox-Gastaut syndrome, age 2 and older (Trokendi XR from age 6)
- Preventive treatment of migraine, age 12 and older
- Phentermine-topiramate ER (Qsymia): weight reduction with diet and exercise in adults with obesity, or with overweight plus a weight-related condition, and in patients 12 and older with obesity. It is a Schedule IV product because of the phentermine.
Topiramate has no psychiatric indication. Every use below is off-label, and acute mania is where it was tested most thoroughly and clearly lost.
Off-Label / Emerging
- Alcohol use disorder (the strongest psychiatric evidence)
- Antipsychotic-associated weight gain
- Binge-eating disorder and bulimia nervosa
- PTSD (small, mixed trials)
- Cocaine and methamphetamine use disorders (unproven)
- OCD augmentation and anger in borderline personality disorder (small trials); essential tremor (a neurology use)
The Evidence by Indication
Alcohol use disorder. In the first trial (Johnson et al., Lancet 2003; 150 patients, 12 weeks, up to 300 mg/day), patients on topiramate had 2.88 fewer drinks per day, 27.6% fewer heavy drinking days and 26.2% more days abstinent than those on placebo. The multisite follow-up (Johnson et al., JAMA 2007; 371 patients, 14 weeks, up to 300 mg/day) started treatment while patients were still drinking heavily and excluded other substance use disorders and depression. It was positive but smaller in the primary analysis, which counted dropouts as relapse: heavy drinking days fell 8.4 percentage points more than with placebo (95% CI 3.1 to 13.8). The prespecified mixed model gave 16.2 points. Kranzler et al. (Am J Psychiatry 2014) enrolled 138 heavy drinkers whose goal was to cut down, not stop, and 200 mg/day reduced heavy drinking days and increased abstinent days.
The 2024 head-to-head trial (Morley et al., Am J Psychiatry 2024; 147 patients, 12 weeks) compared topiramate up to 200 mg/day with naltrexone 50 mg. The primary outcome, heavy drinking days per week, showed only a near-significant time-by-treatment interaction. Topiramate did better on drinks per drinking day, craving, BMI and GGT, withdrawals for side effects were 8% vs 5%, and the authors concluded it was at least as effective as naltrexone. An earlier three-arm trial in Brazil (155 patients, after a week of detoxification) found topiramate better than placebo on time to first relapse and weeks of heavy drinking, with no significant difference from naltrexone (Baltieri et al. 2008). Two trials were negative, one after residential treatment in Thailand (Likhitsathian 2013) and one in combined cocaine and alcohol dependence (Kampman 2013). A 2014 meta-analysis of 7 trials (1,125 participants) found small-to-moderate effects on abstinence and heavy drinking. The APA guideline rates naltrexone and acamprosate 1B and topiramate or gabapentin 2C, and a 2023 JAMA review of 118 trials named naltrexone 50 mg and acamprosate as first-line.
Antipsychotic-associated weight gain. A meta-analysis of 8 trials in schizophrenia spectrum disorders (Correll et al., J Clin Psychiatry 2016; 439 patients, 100 to 400 mg/day) found weight 3.14 kg lower than with the comparator and better total psychopathology (SMD -0.57), with similar discontinuation; clozapine combinations gained more symptom benefit and lost less weight. A 2026 network meta-analysis of 95 trials in schizophrenia spectrum disorders (Stogios et al., JAMA Psychiatry) put semaglutide first (-10.98 kg) and liraglutide second (-5.43 kg), with topiramate (-3.95 kg, 5 trials) and metformin (-3.86 kg, 16 trials) close together. That is an indirect comparison, and only semaglutide and metformin reached a weight change of 5% or more. In bipolar patients on lithium or valproate, topiramate lowered weight 2.5 kg vs a 0.2 kg gain on placebo (Chengappa et al. 2006).
Binge eating and bulimia. In obese adults with binge-eating disorder, topiramate cut binge frequency by 94% vs 46% (McElroy et al., Am J Psychiatry 2003; 61 patients, median dose 212 mg/day). The multicenter trial (McElroy et al., Biol Psychiatry 2007; 394 patients) found 58% remission vs 29%, weight -4.5 kg vs +0.2 kg, and 16% vs 8% stopping for adverse events. In bulimia nervosa, binge or purge days fell 44.8% vs 10.7% (Hoopes et al. 2003; 69 patients, median 100 mg/day), and a 60-patient trial was also positive. Lisdexamfetamine is the only drug approved for binge-eating disorder and fluoxetine the only one approved for bulimia.
PTSD. The trials are small. In 38 civilians, total CAPS did not separate from placebo, though re-experiencing did (Tucker et al. 2007); in 35 civilians, total CAPS improved at a mean of about 103 mg/day (Yeh et al. 2011). As an add-on in 40 veterans it showed no significant benefit, but 55% dropped out on topiramate vs 25% on placebo, too many for firm conclusions (Lindley et al. 2007). In a pilot trial of 30 veterans with PTSD and alcohol use disorder it cut drinking frequency and craving and was associated with lower PTSD severity (Batki et al. 2014). A 2020 network meta-analysis found a medium effect (SMD -0.57) resting on a few small studies. My read: a later option after an SSRI or SNRI and trauma-focused therapy, and a stronger one when heavy drinking is part of the picture.
Stimulant use disorders. One cocaine trial (142 patients, target 300 mg/day) raised the weekly proportion of cocaine nonuse days more than placebo (13.3% vs 5.3%; Johnson et al. 2013). The combined cocaine and alcohol trial missed its primary outcome, topiramate did not increase methamphetamine abstinence (Elkashef et al. 2012), and a 2026 pooled analysis of 12 NIDA trials, topiramate among them, found a signal only for cabergoline. Treat this use as unproven.
Bipolar disorder, where it failed. Four 3-week placebo-controlled monotherapy trials in acute mania (target doses 200 to 600 mg/day) found no separation, while lithium separated in the two that included it (Kushner et al. 2006). Added to lithium or valproate in 287 manic or mixed patients, YMRS fell 40.1% on topiramate and 40.2% on placebo (Chengappa et al. 2006). These trials showed no mania exacerbation or treatment-emergent depression, so in practice topiramate is a reasonable choice in a bipolar patient for weight, drinking or migraine, alongside a real mood stabilizer.
Smaller signals. Small trials suggest benefit in OCD augmentation (Mowla et al. 2010; Berlin et al. 2011, compulsions only, with 28% stopping for adverse effects), anger in borderline personality disorder (Nickel et al. 2004) and essential tremor (Ondo et al. 2006).
The alcohol trials that worked used 200 to 300 mg/day, two to three times the migraine dose, and the label shows cognitive effects rising with dose. Agree with the patient on the target, and on what would make you stop climbing, before you start.
Who Is a Good Candidate?
- A heavy drinker who wants to cut down or stop and also has obesity (the APA guideline names it), binge eating or migraine
- A patient with alcohol use disorder who is on opioids, or will be, so naltrexone is off the table (practice; naltrexone is contraindicated with opioids)
- A patient on an antipsychotic who has gained weight, especially with residual psychotic symptoms or a comorbid drinking or binge-eating problem (practice)
- A patient with binge-eating disorder for whom a stimulant is a poor fit, such as someone with bipolar disorder or a stimulant use history (practice)
Who Is a Poor Candidate?
- A patient whose work depends on verbal fluency or who already has cognitive complaints
- A history of kidney stones, a ketogenic diet, or another carbonic anhydrase inhibitor such as zonisamide or acetazolamide
- Glaucoma (the Topamax Medication Guide asks about it, and it is a Qsymia contraindication)
- A woman who could become pregnant and will not use reliable contraception
- Anorexia nervosa or a low-weight eating disorder, where a drug that suppresses appetite and lowers weight works against treatment (practice)
- Anyone who needs a mood stabilizer for mania
Part 2: Mechanism
Topiramate is a sulfamate-substituted monosaccharide, a fructose derivative. The label says its mechanisms in epilepsy and migraine are unknown and lists four properties found in preclinical work:
- Voltage-dependent sodium channel blockade
- Enhanced GABA activity at some GABA-A receptor subtypes
- AMPA/kainate glutamate receptor antagonism
- Carbonic anhydrase inhibition, mainly isozymes II and IV. Renal bicarbonate loss from this inhibition causes the hyperchloremic, non-anion-gap metabolic acidosis, and carbonic anhydrase inhibitors favor stones by lowering urinary citrate and raising urinary pH.
Pharmacokinetics. Absorption is rapid, with peaks about 2 hours after a dose, and food does not change bioavailability. The mean half-life is 21 hours, so steady state takes about 4 days. About 70% of a dose leaves unchanged in the urine; six minor metabolites each account for less than 5%. Clearance falls 42% in moderate and 54% in severe renal impairment, 26% in moderate to severe hepatic impairment, and about 21% in older adults, in proportion to their renal function. Hemodialysis removes it at 4 to 6 times the normal rate. In vitro, topiramate mildly inhibits CYP2C19 and mildly induces CYP3A4, and it does not inhibit the other major CYP enzymes tested.
The extended-release capsules stretch out the curve. Trokendi XR's half-life was about 31 hours after repeated doses, and Qudexy XR's effective half-life is about 56 hours, with steady state in about 5 days.
The interactions that matter run in a few predictable directions: renal function sets the dose, because about 70% leaves unchanged in the urine; enzyme inducers still lower it (carbamazepine by 40%, phenytoin by 48%); and its own effects on other drugs show up mainly at high doses (ethinyl estradiol, lithium) or through shared toxicity (valproate, other carbonic anhydrase inhibitors).
Part 3: Before You Start: Workup and Candidacy
The workup is short, and most of it is aimed at the acid-base, kidney, eye and pregnancy risks.
| Assessment | Why |
|---|---|
| Serum bicarbonate (basic metabolic panel) | The label recommends baseline and periodic bicarbonate; acidosis can occur at any time during treatment |
| Creatinine and estimated creatinine clearance | Below 70 mL/min/1.73 m², half the usual dose; the APA guideline suggests checking renal function before starting |
| Kidney stone history, ketogenic diet, other carbonic anhydrase inhibitors | Each adds to stone risk; the label says to avoid combining topiramate with other acid-producing drugs or a ketogenic diet |
| Eye history, especially glaucoma | The drug-induced angle closure can occur at any age, usually within the first month; the Medication Guide asks about glaucoma, and Qsymia is contraindicated in it |
| Baseline cognition | The APA guideline says a baseline cognitive assessment may be appropriate; it gives you a reference when the patient later complains of word-finding trouble |
| Pregnancy potential and contraception | Oral clefts form in the first trimester, often before pregnancy is known; the Qsymia label calls for a negative pregnancy test before starting and monthly |
| Mood and suicidality | The antiepileptic-class warning on suicidal thoughts and behavior applies |
| Weight and eating history | Expected weight loss is a benefit for most and a hazard in a low-weight eating disorder |
| Medication list | Valproate, lithium, hormonal contraceptives, metformin, hydrochlorothiazide, carbamazepine or phenytoin, anticholinergic drugs, other CNS depressants (Part 8) |
| GGT (in alcohol use disorder) | Optional; the trials used it as an objective marker of drinking |
Ask about seizure history even when you are prescribing for drinking or weight, because it changes how carefully you taper.
Part 4: How to Start and Dose
Kidney impairment, dialysisFDA labelCreatinine clearance below 70 mL/min/1.73 m²: one-half of the usual adult dose. Hemodialysis: a supplemental dose may be required.In practiceHalf the usual dose below a creatinine clearance of 70 mL/min/1.73 m², including age-related decline in older adults.
Childrenepilepsy, migraine4 rows
Extended-release and solution productsQudexy XR, Trokendi XR, Eprontia9 rows
With carbamazepine or phenytoin1 row
Stopping1 row
Formulations
- Topamax tablets 25, 50, 100 and 200 mg. Do not break them: they taste bitter.
- Topamax Sprinkle Capsules 15 and 25 mg, swallowed whole or opened onto a teaspoon of soft food and swallowed without chewing. Bioequivalent to the tablets.
- Trokendi XR extended-release capsules 25, 50, 100 and 200 mg, once daily, swallowed whole. Contraindicated with alcohol within 6 hours before or after a dose, because alcohol changes how the capsule releases the drug.
- Qudexy XR extended-release capsules 25, 50, 100, 150 and 200 mg, once daily, which can be opened and sprinkled on soft food.
- Eprontia oral solution 25 mg/mL, measured with a calibrated device.
- Qsymia (phentermine/topiramate ER) 3.75/23, 7.5/46, 11.25/69 and 15/92 mg, once in the morning.
Generic immediate-release tablets, sprinkle capsules, oral solution, extended-release capsules and phentermine-topiramate are all listed on DailyMed.
Start Low, Go Slow
In the label, rapid titration and higher starting doses produced more cognitive dysfunction. The add-on epilepsy trials raised the dose 100 to 200 mg/day each week, and cognitive events reached 42% at 200 to 400 mg/day vs 14% on placebo. The migraine trials raised it 25 mg/day each week, and rates were 19% at 50 mg, 22% at 100 mg and 28% at 200 mg vs 10%. For psychiatric uses I start 25 mg at night and add 25 mg each week, the migraine increment, so the 200 mg/day alcohol target takes eight weeks to reach; say so at the start. Patients who are struggling can stay on a step for two weeks; the label allows longer intervals between dose changes.
The immediate-release label divides doses twice daily. With a 21-hour half-life, giving the whole psychiatric dose at night is common practice, not label text, and splitting the dose is the first move when side effects track the peak. In drinkers, my practice is immediate-release topiramate or Qudexy XR rather than Trokendi XR.
Switching Between Forms
Moving from immediate-release to an extended-release capsule at the same total daily dose, given once daily, produced comparable steady-state levels in the bioavailability studies of both products.
Dose Adjustments and Special Populations
- Renal: half the usual dose below a creatinine clearance of 70 mL/min/1.73 m², including age-related decline in older adults.
- Hepatic: no topiramate label adjustment (Part 9).
- Inducers: carbamazepine and phenytoin lower topiramate levels by 40% to 48%; a dose adjustment may be needed when the inducer starts or stops.
Missed dose
- One dose: take it when remembered unless the next dose is within 6 hours, never double, and call if more than one dose is missed (Topamax label; the XR labels word it differently).
- Several days: with a 21-hour half-life, little immediate-release drug is left after about 4 days.
- Restarting after a gap: restart low and step back up, because fast titration brings more cognitive effects (practice, not label).
What to tell the patient at the first prescription
- What to expect and when: the dose rises 25 mg a week, and the trials judged benefit at 12 to 14 weeks.
- Early side effects: tingling, changed taste, less appetite and sleepiness while the dose rises. Tell me early about trouble finding words.
- Call me about: sudden blurred vision or eye pain, low mood or suicidal thoughts, confusion or vomiting (above all with valproate), a rash, or severe flank pain.
- How to take it: at bedtime with plenty of fluids, and no driving until you know how it affects you. If you could become pregnant, an IUD or the contraceptive injection is the safest choice, because topiramate can weaken pills, patches and rings.
- Do not stop on your own: we taper, even without a seizure history.
- Next visit: within the first month, then blood work about a month after the target dose.
Part 5: Monitoring
The label asks for baseline and periodic bicarbonate but sets no schedule. The intervals below are practice.
| Parameter | Baseline | Follow-up |
|---|---|---|
| Bicarbonate | ✓ | About a month after reaching the target dose, then every 6 to 12 months and with any dose increase |
| Creatinine | ✓ | With the bicarbonate checks; more often in older adults |
| Potassium | If on a diuretic | After adding hydrochlorothiazide or another non-potassium-sparing diuretic |
| Cognition, word-finding, fatigue | ✓ | Every visit during titration |
| Vision and eye pain | ✓ | Ask at each visit in the first month; stop the drug for acute blurring or eye pain |
| Mood and suicidality | ✓ | Every visit early, then routinely |
| Weight | ✓ | Every visit; in young people, also height |
| Drinking outcomes, GGT | In AUD | Heavy drinking days at each visit; GGT if useful |
| Lithium level | If on lithium | Recheck once topiramate reaches higher doses |
| Ammonia | Not routine | Unexplained lethargy, vomiting or confusion, or hypothermia with valproate |
| INR, glucose | If relevant | INR with warfarin; glucose with pioglitazone, glyburide or metformin |
Bicarbonate drops are usually mild to moderate (an average of about 4 mEq/L at 400 mg/day in adults), and values below 10 mEq/L are rare. Diarrhea, renal disease, severe respiratory disease and a ketogenic diet add to the drop. If acidosis persists, the label says to lower the dose or taper off, and to consider alkali treatment if you continue. Chronic, untreated acidosis may raise the risk of stones and nephrocalcinosis and may cause osteomalacia or osteoporosis.
If it isn't working
- First, check: adherence, the dose actually reached (200 mg/day for drinking, 100 to 200 mg/day for weight) and time on it. Ask about word-finding trouble and tingling, which lead patients to skip doses.
- At 12 to 14 weeks: judge the trial, since that is how long the studies ran, by heavy drinking days (GGT helps) or by weight.
- Do not: climb past 300 mg/day for drinking, keep raising the dose while word-finding worsens, or count on it for mania.
- Then: for drinking, naltrexone or acamprosate; for antipsychotic weight gain, metformin or a GLP-1 agonist; for binge eating, lisdexamfetamine if a stimulant fits. Taper topiramate by 25 to 50 mg a week.
Part 6: Side Effects and How to Manage Them
The best placebo-controlled adverse-event data at a slow titration come from the migraine program, which used 25 mg/week steps and a top dose of 200 mg/day. In those trials 25% of patients on topiramate stopped for adverse reactions vs 10% on placebo, most often for paresthesia (7%), fatigue (4%), nausea (4%) and difficulty concentrating (3%).
| Adverse reaction (migraine trials) | Topiramate 100 mg/day | Placebo |
|---|---|---|
| Paresthesia | 51% | 6% |
| Anorexia | 15% | 6% |
| Nausea | 13% | 8% |
| Diarrhea | 11% | 4% |
| Weight loss (reported as an event) | 9% | 1% |
| Taste perversion | 8% (15% at 50 mg) | 1% |
| Difficulty with memory | 7% | 2% |
| Language problems | 6% | 2% |
| Difficulty with concentration | 6% | 2% |
| Mood problems | 6% | 2% |
Cognitive Effects and Word-Finding
The label groups these as cognitive dysfunction (confusion, slowing, poor concentration, memory trouble and language problems, especially word-finding), depression or mood problems, and somnolence or fatigue. In the add-on epilepsy trials, speech problems and psychomotor slowing were each 13% vs 2%; in the 2007 alcohol trial, difficulty concentrating was 14.8% vs 3.2%. In a neuropsychological series of 18 epilepsy patients, verbal fluency, verbal learning and verbal IQ fell the most, and verbal fluency and learning improved in the subgroup retested after the dose was cut or the drug stopped (Thompson et al. 2000, a retrospective study). In veterans with PTSD and drinking problems, learning and memory dipped early, with significant recovery by the end of 12 weeks (Batki et al. 2014). In my experience it is the side effect patients complain about most, and many describe it as not being able to think straight.
- Management: slow titration, the lowest dose that does the job, bedtime dosing or a split dose, and a step back to the last tolerated dose. If word-finding trouble persists at the dose that works, the trade is usually not worth it.
Paresthesia, Taste and Appetite
Tingling in the hands, feet or face is the most frequent side effect, in about half of patients in the migraine trials at 100 mg/day and in the 2007 alcohol trial. Taste change (23.0% vs 4.8% in that trial) and reduced appetite follow. In the migraine trials most adverse reactions were more frequent during titration than during maintenance. Mean weight change was 0%, -2%, -3% and -4% for placebo and 50, 100 and 200 mg/day.
- Management: warn in advance so tingling does not frighten the patient, and hold the dose steady for a week or two if it is bothersome.
Somnolence, Fatigue and Dizziness
Somnolence was the most common complaint in the add-on epilepsy trials (29% vs 12%), with dizziness 25% vs 15% and fatigue 15% vs 13%. Fatigue and somnolence were dose-related and more common during titration in the migraine trials. Counsel about driving until the patient knows how it affects them.
Mood
Depression and mood problems were dose-related in the epilepsy and migraine programs, and the antiepileptic-class warning applies (Part 7). The mania trials showed no mood worsening, but in an open weight-loss study in bipolar patients, higher manic and depressive scores predicted early dropout (McElroy et al. 2007). Ask about mood at each early visit.
Kidney Stones
In the adult add-on epilepsy trials, 1.5% developed kidney stones, about 2 to 4 times the expected rate, and men more often than women. The label recommends hydration to reduce new stones and avoiding other carbonic anhydrase inhibitors and ketogenic diets.
Bleeding
Bleeding events were 4.5% vs 3.0% in pooled adult trials, mostly minor (nosebleeds, bruising, heavier periods); serious cases often involved SSRIs, NSAIDs or anticoagulants.
Other
- Hyperammonemia: dose-related, sometimes without symptoms, more frequent with valproate (Part 8). In adolescents in the migraine trials it reached 26% at 100 mg/day vs 9% on placebo.
- Postmarketing: hepatic failure (including deaths), hepatitis, pancreatitis, maculopathy, and lower INR in patients on warfarin.
Part 7: Toxicity, Overdose, and Boxed Warnings
Topiramate carries no boxed warning. In March 2026 the labels of Topamax, Trokendi XR, Qudexy XR, Eprontia and Qsymia added warnings for DRESS (multiorgan hypersensitivity) and for anaphylaxis and angioedema. Topamax, which listed no contraindications before, now lists hypersensitivity (below). In August 2026 the Qudexy XR label added a warning, based on in vitro findings for topiramate products, of serious and potentially life-threatening cardiac rhythm and conduction abnormalities, particularly with underlying cardiac disorders or arrhythmias. It asks you to weigh benefit carefully against risk in clinically important structural or functional heart disease, to tell patients to report palpitations, fainting, dizziness, chest pain or breathlessness, and to stop the drug for excessive conduction slowing or significant arrhythmia. The Topamax, Trokendi XR, Eprontia and Qsymia labels current in November 2026 do not carry it; applying the same caution to any topiramate product is my practice.
Contraindications
- All topiramate products: a history of hypersensitivity reaction to topiramate or any inactive ingredient.
- Trokendi XR only: alcohol use within 6 hours before or after a dose.
- Qsymia: pregnancy, glaucoma, hyperthyroidism, an MAOI now or within 14 days, and hypersensitivity or idiosyncrasy to sympathomimetic amines.
Serious Warnings
- Acute myopia with secondary angle-closure glaucoma: sudden blurred vision or eye pain, usually within the first month, reported in children as well as adults. Stop the drug as quickly as possible; untreated raised eye pressure can cause permanent vision loss. Visual field defects can also occur and were mostly reversible.
- Suicidal thoughts and behavior (antiepileptic class): in 199 pooled trials of 11 antiseizure drugs, 0.43% on drug vs 0.24% on placebo, about one extra case per 530 patients treated. In psychiatric trials the relative risk was 1.5, with 2.9 extra patients with events per 1,000.
- Oligohidrosis and hyperthermia: reduced sweating and raised body temperature, mostly in children, sometimes after heat exposure. Take extra care with other drugs that predispose to heat illness, including other carbonic anhydrase inhibitors and anticholinergic drugs.
- DRESS, Stevens-Johnson syndrome and toxic epidermal necrolysis, anaphylaxis and angioedema: stop at the first rash unless it is clearly unrelated, and evaluate fever with lymphadenopathy or facial swelling even without rash.
- Withdrawal seizures: taper even in patients without epilepsy (Part 10).
- Bone density and growth in children: lower lumbar spine bone mineral density and slower weight gain over a year of treatment, with a similar trend for height.
Overdose
Reported effects include seizures, drowsiness, speech disturbance, blurred or double vision, stupor, low blood pressure, agitation, dizziness and severe metabolic acidosis. Most cases were not severe, but deaths have occurred in overdoses involving topiramate. Care is supportive, and hemodialysis removes topiramate effectively. Poison Help (1-800-222-1222) or a toxicologist can advise.
Part 8: Drug Interactions
Most of these come from the label's interaction studies. The two that bite psychiatrists most often are valproate and hormonal contraception.
| Interaction | Effect | Risk | Action |
|---|---|---|---|
| Valproate | Hyperammonemia with or without encephalopathy, and hypothermia, even in patients who tolerated each drug alone; levels change little (topiramate down 14%, valproate down 11%) | HIGH | Warn about lethargy, vomiting and confusion; check ammonia if they or hypothermia appear |
| Estrogen-containing and progestin-only contraceptives | Ethinyl estradiol exposure fell 18% to 30% at 200 to 800 mg/day (studied with valproate); no significant change at 50 to 200 mg/day alone. The label warns of lower efficacy and breakthrough bleeding, especially above 200 mg/day | HIGH | Ask about bleeding changes, but the label says efficacy can fall even without breakthrough bleeding. The CDC's 2024 criteria group topiramate with the enzyme-inducing anticonvulsants, at any dose: combined methods and progestin-only pills category 3, the implant 2, IUDs and DMPA 1, with other methods encouraged for long-term users |
| Other carbonic anhydrase inhibitors (zonisamide, acetazolamide); ketogenic diet | Worse acidosis and more kidney stones | HIGH | Avoid; if unavoidable, monitor bicarbonate closely |
| Alcohol and other CNS depressants (benzodiazepines, opioids, sleep aids) | Additive sedation and cognitive effects; with Trokendi XR, alcohol alters release (peak too high, then too low) | MODERATE | Label: use with extreme caution, and the Topamax Medication Guide tells patients not to drink. In alcohol use disorder, explain that the aim is less drinking and that alcohol adds to the drowsiness (practice). Trokendi XR is contraindicated within 6 hours of alcohol |
| Carbamazepine, phenytoin | Topiramate down 40% and 48%; phenytoin up to 25% higher in some patients | MODERATE | Dose adjustment may be needed, including when the inducer stops |
| Lithium | No change at 200 mg/day; lithium AUC up 26% at topiramate doses up to 600 mg/day | MODERATE | Check a lithium level after reaching higher doses |
| Metformin | Metformin AUC up 25%; the metformin label warns that carbonic anhydrase inhibitors may raise lactic acidosis risk | MODERATE | The pair is common for antipsychotic weight gain; monitor bicarbonate and renal function more often |
| Hydrochlorothiazide | Topiramate AUC up 29%; potassium falls more with the combination | LOW | May need a lower topiramate dose; check potassium |
| Anticholinergic drugs (benztropine, for example) | Added risk of reduced sweating and heat illness | LOW | Counsel about heat, hydration and exercise |
| Warfarin; SSRIs, NSAIDs, anticoagulants | Postmarketing reports of lower INR with warfarin; more bleeding events with drugs that affect platelets or clotting | LOW | Check INR after starting; ask about bruising |
| Amitriptyline | 12% higher exposure in a study, but some patients had large increases | LOW | Adjust amitriptyline by clinical response |
| Risperidone, haloperidol, venlafaxine, propranolol | Risperidone exposure fell 16% to 33% at 250 to 400 mg/day, judged not clinically significant; no change with the others | NONE | No adjustment |
Pioglitazone and glyburide exposure fall modestly with topiramate, so watch glucose control.
A bipolar patient on valproate who has gained weight is a common candidate, and the add-on trial supports it for weight without mood worsening. Tell the patient and household before the first dose that new sleepiness, vomiting or confusion means an ammonia level that day, even after months on valproate alone.
Part 9: Special Populations
Pregnancy
The label says topiramate can cause fetal harm. In the North American AED Pregnancy Registry, oral clefts occurred in 1.4% of topiramate-exposed infants vs 0.3% with a reference antiseizure drug and 0.11% in unexposed infants of mothers without epilepsy (relative risk 12.5 vs the background population). With isolated clefts excluded, major malformations were 4.1% vs 1.8% and 1.1%. Small-for-gestational-age births were 19.7% vs 7.9% and 5.4% in the registry and 25% vs 9% in the Norwegian birth registry, with higher rates at higher doses and with use continued into the third trimester. Preterm delivery has been associated in limited data, and maternal or neonatal metabolic acidosis is possible.
The neurodevelopmental data conflict. In the Nordic SCAN-AED cohort (Bjørk et al., JAMA Neurology 2022), children of mothers with epilepsy exposed to topiramate monotherapy had autism in 4.3% and intellectual disability in 3.1% by age 8, vs 1.5% and 0.8% in unexposed children of mothers with epilepsy, with adjusted hazard ratios of 2.8 and 3.5; the authors reported higher hazard ratios at higher doses of the antiseizure drugs studied. A related exploratory Nordic analysis found more ADHD (adjusted HR 2.38) (Dreier et al. 2023). In two large US databases (Hernández-Díaz et al., NEJM 2024), which measured exposure in the second half of pregnancy, autism by age 8 was 6.2% after topiramate exposure vs 4.2% without antiseizure drugs among children of mothers with epilepsy, but the adjusted hazard ratio was 0.96 (0.56 to 1.65), while valproate stayed elevated (2.67). A 2026 analysis of exposure in the last 60 days of pregnancy found more neurodevelopmental disorders in its pooled Canadian cohorts, with a wide interval (HR 1.56, 1.04 to 2.34; 69 exposed cases). The US label does not address neurodevelopment. In 2023 the EMA's safety committee reviewed three observational studies (two, which used largely the same datasets, showing a two- to threefold risk, and one showing none). It kept the existing EU contraindication in pregnancy for migraine prevention and weight management, advised against use in pregnancy for epilepsy unless no other suitable treatment is available, and added a pregnancy prevention program for anyone who can become pregnant: a pregnancy test before starting, counselling on highly effective contraception, and at least an annual review.
- Framework: the label asks you to weigh fetal risk hardest when topiramate is used for a condition "not usually associated with permanent injury or death," and weight gain and binge eating fit that description. In a patient who could become pregnant, start it only with reliable contraception (an IUD or DMPA, which the CDC rates category 1 with topiramate; Part 8), document the conversation, and favor an alternative when pregnancy is planned.
- If pregnancy occurs: taper rather than stopping abruptly, and switch to an option with better pregnancy data (practice). Clefts form in the first trimester, often before the pregnancy is known.
- Qsymia: contraindicated in pregnancy, dispensed only by certified pharmacies under a REMS, with a negative pregnancy test before starting and monthly during treatment.
- Encourage enrollment in the North American Antiepileptic Drug Pregnancy Registry (1-888-233-2334).
Lactation
Topiramate passes into milk at concentrations similar to maternal plasma (mean milk-to-plasma ratio 0.86 in a small study), yet the breastfed infants in that study had very low plasma levels and no adverse effects (Ohman et al. 2002). The label notes reports of diarrhea and somnolence in breastfed infants. Breastfeeding is not recommended on Qsymia. If a mother continues topiramate, watch the infant for sleepiness, poor feeding and diarrhea.
Elderly
- Only 3% of trial patients were over 60. Clearance falls in step with renal function, so dose by creatinine clearance.
- The APA guideline advises caution in patients at risk for falls.
Renal Impairment
Below a creatinine clearance of 70 mL/min/1.73 m², use half the usual dose. Hemodialysis clears topiramate 4 to 6 times faster than normal kidneys, so a supplemental dose may be needed. Qsymia is capped at 7.5/46 mg when creatinine clearance is under 50 mL/min and should be avoided in end-stage renal disease on dialysis.
Hepatic Impairment
Clearance falls about 26% in moderate to severe impairment, and the Topamax label sets no dose change. Reduced hepatic mitochondrial activity may raise the risk of hyperammonemia. For Qsymia, the maximum is 7.5/46 mg in moderate impairment, and it should be avoided in severe impairment.
Pediatric / Adolescent
Topiramate is approved for epilepsy from age 2 (Trokendi XR from 6) and for migraine from 12; Qsymia is approved for obesity from 12. Psychiatric uses in young people are off-label. Children carry more of the oligohidrosis, acidosis, bone density and growth risks.
Part 10: Discontinuation and Taper
The label says to withdraw antiseizure drugs gradually in patients with or without a history of seizures, to reduce the risk of seizures, and to monitor appropriately when rapid withdrawal is medically required.
- Usual taper: in the migraine trials, patients coming off had their daily dose lowered by 25 to 50 mg each week, and the same steps are a sensible taper from psychiatric doses (practice).
- Qsymia 15/92 mg: take it every other day for at least a week before stopping, because of the seizure risk.
- Stopping fast: acute angle-closure symptoms, DRESS, a serious rash or anaphylaxis warrant stopping right away, with monitoring in a patient with seizure risk.
- Duration: the APA guideline found no specific evidence on how long to treat alcohol use disorder, and the trials ran 12 to 14 weeks. Reassess at intervals with the patient, weighing drinking, side effects and relapse history.
Switching and Combining
- With naltrexone: the topiramate label lists no interaction with naltrexone, and no published trial has tested the pair for efficacy. Adding one to a partial response on the other, or overlapping them during a switch, is practice; naltrexone still requires the patient to be off opioids.
- With an antipsychotic: topiramate did not change haloperidol levels and lowered risperidone exposure only modestly (Part 8). Use the usual weekly steps, and counsel about heat when the regimen is anticholinergic, as with clozapine, olanzapine or benztropine (practice).
Part 11: Topiramate vs the Alternatives
| Comparison | Topiramate Advantage | Alternative Advantage |
|---|---|---|
| vs Naltrexone (AUD) | Usable with opioids; weight loss; better drinks per drinking day, craving and GGT in the 2024 head-to-head trial | First-line (APA 1B); no titration; main side effects in the 2023 review were nausea and vomiting; a monthly injection exists |
| vs Acamprosate (AUD) | Reduces heavy drinking days in patients who are still drinking (Kranzler 2014); twice-daily or nightly dosing | First-line (APA 1B); prevents return to any drinking (NNT 11 in the 2023 review); its main side effect is diarrhea |
| vs Gabapentin (AUD) | Weight loss; the APA review rated the evidence for topiramate's drinking benefit moderate in strength, and gabapentin's benefit on abstinence low | Same APA rating (2C); adverse effects no different from placebo in its main AUD trial; the APA notes misuse potential |
| vs Metformin (antipsychotic weight gain) | Similar weight effect in an indirect comparison (-3.95 vs -3.86 kg in the 2026 network meta-analysis); psychopathology improved in small schizophrenia trials (Correll 2016); treats comorbid drinking, binge eating or migraine | More than three times as many trials (16 vs 5); reached a 5% or greater weight change in that analysis; improved insulin resistance in a 2014 meta-analysis, where topiramate was not listed for it |
| vs Semaglutide or liraglutide (antipsychotic weight gain) | Oral; no injection | Much larger weight loss (semaglutide -10.98 kg vs placebo) |
| vs Lisdexamfetamine (binge-eating disorder) | Not a stimulant; an option with bipolar disorder or stimulant misuse risk | The only FDA-approved drug for binge-eating disorder |
| vs Qsymia (weight) | No phentermine, so no Schedule IV status, no sympathomimetic stimulation and no REMS | FDA-approved for weight; 9.8% to 10.9% weight loss at the top dose vs 1.2% to 1.6% on placebo over a year |
Topiramate makes the most sense where one drug can reach two problems: the heavy drinker with obesity, the patient on olanzapine who now binge eats, the migraine patient who drinks too much. Outside that overlap, my first choices are naltrexone or acamprosate for drinking and metformin or a GLP-1 agonist for antipsychotic weight gain.
The Bedside Cheat Sheet
What it is
- Anticonvulsant: sodium channel, GABA-A, AMPA/kainate and carbonic anhydrase actions
- Half-life ~21 h; ~70% excreted unchanged by the kidney
- Approved: epilepsy (age 2+), migraine prevention (12+); Qsymia for weight
- Off-label: AUD (APA 2C), antipsychotic weight gain, binge eating; failed in mania
Starting and dosing
- Tablets 25 / 50 / 100 / 200 mg; sprinkle 15 / 25 mg; XR capsules; 25 mg/mL solution
- 25 mg at night, +25 mg each week
- AUD 200 mg/day (to 300); weight 100–200 mg/day; migraine 100 mg/day
- CrCl under 70: half dose
- No Trokendi XR in drinkers
Side effects that matter
- Word-finding and slowed thinking: worse with fast titration and high doses
- Paresthesia (about half), taste change, appetite and weight loss
- Metabolic acidosis; kidney stones (1.5%)
- Acute myopia and angle-closure glaucoma, usually in month 1
Don't forget
- Teratogen: clefts, small babies; plan contraception first (IUD or DMPA)
- Hormonal contraceptive efficacy may fall, especially above 200 mg/day
- Bicarbonate and creatinine at baseline, then periodically
- With valproate: hyperammonemia and hypothermia
- Lithium level at high doses; taper to stop
Before the first dose, have the patient name as many animals as they can in a minute and write down the number. Verbal fluency was among the measures that fell most in the epilepsy series, and a second count at the target dose turns a vague complaint into something you can weigh against fewer heavy drinking days.